Navigation Links
FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer

WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug Administration advisory committee on Wednesday voted against approving two drugs for the prevention of prostate cancer, the third-highest cancer killer of men.

The panel voted 17-0, with one abstention, that the risks of Merck's Proscar outweighed its benefits, according to the Associated Press. And in a similar vote, the panel voted 14-2, with two abstentions, against GlaxoSmithKline's Avodart. Both drugs are already approved to treat enlarged prostates.

"In a setting like this, the onus is on the drug to be completely safe, and to show benefit, and I don't think it reached that level," said panel Chairman Dr. Wyndham Wilson, of the National Cancer Institute.

The FDA does not have to heed the advice of its advisory panels, but it typically does.

Research presented to the panel by Merck and GlaxoSmithKline showed a 25 percent decrease in the incidence of low-grade prostate tumors among users of the drugs.

But concern that a small number of men taking the drugs actually developed more aggressive tumors led the panelists to find that the risk of aggressive tumors outweighed the benefit of reducing tumors that are seldom fatal, the wire service reported.

FDA regulators already had several concerns about using the medications for the prevention of prostate cancer, the AP reported. For one thing, black men, who are at high risk for the disease, were underrepresented in the clinical trials. "The applicability to African-American men is not known due to marked under-representation," the FDA's online review stated.

Blacks made up just 4 percent of Merck's patients and only 2 percent of Glaxo's patients, according to the AP.

The panel of outside experts assembled by the FDA is also likely to discuss the overall value of preventing low-grade tumors. According to the FDA, more than three-quarters of the tumors the drugs prevent are slow-growing, meaning they are non-aggressive and probably not life-threatening for anyone with a life expectancy of less than 20 years.

But even if the tumors aren't aggressive, Glaxo has said they often involve unnecessary treatment and biopsies, or surgical procedures, to diagnose cancer, that pose risks of their own.

Also, slightly more aggressive tumors were seen in men taking Avodart and Proscar, compared with those taking placebo pills, according to the FDA. But the pharamaceutical companies say the drugs simply make those tumors easier to detect because they shrink the prostate.

The U.S. National Cancer Institute estimates that 217,730 men will be diagnosed with prostate cancer this year and 32,050 men will die of it.

More information

For more on prostate cancer, visit the U.S. National Library of Medicine.

-- Margaret Steele

SOURCES: U.S. Food and Drug Administration; Associated Press

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
2. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
3. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
4. Teens Should Get Meningitis Booster Shot: CDC Panel
5. Expert Panel Links Popular Bone Drugs to Rare Fracture
6. FDA Panel to Mull Ban on Diet Drug Meridia
7. Experts Support FDA Panels Backing of New Blood Thinner
8. Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
9. FDA Panel Seems Skeptical Over Key Avandia Data
10. FDA Panel Appears Skeptical Over Key Avandia Data
11. NJIT professor heads panel studying sudden car acceleration
Post Your Comments:
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any ... opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with the ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology: